AMPIO PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.38 USD | +18.38% |
|
+11.44% | -81.46% |
| Apr. 15 | Ampio Pharmaceuticals, Inc.(NYSEAM:AMPE) dropped from S&P TMI Index | CI |
| Mar. 27 | Ampio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 42.13 | 92.49 | 294.2 | 129.5 | 3.397 | 1.706 |
| Enterprise Value (EV) 1 | 34.55 | 87.43 | 277.8 | 95.61 | -8.487 | -1.966 |
| P/E ratio | 1.29 x | -4.13 x | -17.3 x | -5.68 x | -0.15 x | -0.19 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -3.49 x | -5.05 x | -19 x | -4.91 x | 0.44 x | 0.21 x |
| EV / FCF | -4.09 x | -10.5 x | -27.7 x | -17.2 x | 0.6 x | 0.37 x |
| FCF Yield | -24.4% | -9.54% | -3.62% | -5.83% | 167% | 273% |
| Price to Book | 8.36 x | 14.4 x | 17.6 x | 4.75 x | 0.29 x | 0.51 x |
| Nbr of stocks (in thousands) | 356 | 529 | 617 | 757 | 754 | 832 |
| Reference price 2 | 118.4 | 174.9 | 477.0 | 171.0 | 4.504 | 2.050 |
| Announcement Date | 3/18/19 | 2/21/20 | 3/3/21 | 3/29/22 | 3/27/23 | 3/27/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -9.903 | -17.3 | -14.66 | -19.48 | -19.33 | -9.391 |
| EBIT 1 | -11.18 | -18.58 | -15.83 | -20.57 | -20.38 | -9.518 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | 33.99 | -13.63 | -15.89 | -17.08 | -16.34 | -8.632 |
| Net income 1 | 33.99 | -13.63 | -15.89 | -17.08 | -16.34 | -8.632 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | 91.90 | -42.32 | -27.59 | -30.10 | -29.32 | -10.66 |
| Free Cash Flow 1 | -8.446 | -8.34 | -10.05 | -5.575 | -14.16 | -5.372 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/18/19 | 2/21/20 | 3/3/21 | 3/29/22 | 3/27/23 | 3/27/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -3.851 | -9.228 | -6.97 | -4.988 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -3.628 | -6.224 | -5.636 | -2.07 |
| Net income 1 | -3.628 | -6.224 | -5.636 | -2.07 |
| Net margin | - | - | - | - |
| EPS 2 | -6.000 | -12.00 | -6.000 | -3.000 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 11/10/21 | 3/29/22 | 5/16/22 | 8/9/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 7.59 | 5.06 | 16.4 | 33.9 | 11.9 | 3.67 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -8.45 | -8.34 | -10 | -5.57 | -14.2 | -5.37 |
| ROE (net income / shareholders' equity) | -235% | -233% | -133% | -76.2% | -83.6% | -114% |
| ROA (Net income/ Total Assets) | -47.6% | -82.8% | -53.7% | -41.7% | -48.6% | -61.6% |
| Assets 1 | -71.34 | 16.45 | 29.62 | 40.97 | 33.61 | 14.02 |
| Book Value Per Share 2 | 14.20 | 12.20 | 27.20 | 36.00 | 15.60 | 4.030 |
| Cash Flow per Share 2 | 20.50 | 12.40 | 26.90 | 44.70 | 16.80 | 4.910 |
| Capex 1 | 0.56 | 0.02 | 0.06 | 0.1 | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/18/19 | 2/21/20 | 3/3/21 | 3/29/22 | 3/27/23 | 3/27/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -81.46% | 431K | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +2.74% | 22.18B | |
| -16.67% | 21.2B | |
| -8.98% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- AMPE Stock
- Financials Ampio Pharmaceuticals, Inc.
